Search

Displaying results 2261 - 2270 of 6951 in total
  1. Drug

    Vestronidase alfa

    go.drugbank.com/drugs/DB12366
    ApprovedInvestigational

    Vestronidase alfa was FDA-approved on November 17th, 2017 under the trade name Mepsevii as an intravenous infusion for the treatment of pediatric and adult patients. … Vestronidase alfa is an enzyme replacement therapy for the treatment of mucopolysaccharidosis type VII (MPS VII), also known as Sly syndrome, which is an inherited, rare genetic metabolic condition that

  2. Drug

    Nevirapine

    go.drugbank.com/drugs/DB00238
    ApprovedInvestigational

    A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS.

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  3. Drug

    Human thrombin

    go.drugbank.com/drugs/DB11571
    ApprovedInvestigational

    Human thrombin is a sterile solution, pH 6.8-7.2, containing highly purified human thrombin for the activation of clotting.

    Mixtures: ARTISS SOLUTIONS FOR SEALANT, DEEP FROZEN
  4. Drug

    Zotepine

    go.drugbank.com/drugs/DB09225
    ApprovedWithdrawn

    In the EMA, by 2015 it was under pharmacovigilance studies for the potential treatment of acute renal failure.[L1314]

    Categories: Dopamine D2 Receptor Antagonists, Serotonin Receptor Antagonists
  5. Drug

    Obiltoxaximab

    go.drugbank.com/drugs/DB05336
    Approved

    Obiltoxaximab, an affinity-enhanced monoclonal antibody (Mab), is used for prevention and treatment of infection and death caused by anthrax toxin.

    Categories: Antiinfectives for Systemic Use
  6. Drug

    Sutimlimab

    go.drugbank.com/drugs/DB14996
    ApprovedInvestigational

    [A245159] Treatment options for patients with CAD are limited. … [A245154] Notably, none of these agents are approved for use in the treatment of CAD.

  7. Drug

    Simeprevir

    go.drugbank.com/drugs/DB06290
    ApprovedWithdrawn

    or second-line threapies for treatment-naïve patients as adjunct to sofosbuvir treatment for genotype 1 or PEG-Interferon/ribavirin combination therapy for genotype 1 or 4. … According to 2017 American Association for the Study of Liver Diseases (AASLD) and 2015 consensus guidelines from the Canadian Association for the Study of the Liver (CASL), simeprevir can be used as first-line

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  8. Drug

    Bovine type I collagen

    go.drugbank.com/drugs/DB10771
    ApprovedInvestigational

    Bovine type I collagen is also used as a health supplement for bones and joints [A32698]. … Often combined with other ingredients, such as fibroblasts and keratinocytes, it allows for accelerated and effective wound healing [L2427], [L2450].

  9. Drug

    N-alkyl ethylbenzyl dimethyl ammonium (C12-C14)

    go.drugbank.com/drugs/DB11202
    Approved

    Employed in a great variety of cleaning agents and sanitizing agents, it possesses relatively broad gram-positive and gram-negative antibacterial activities and relatively little chance for systemic absorption

  10. Drug

    Lumacaftor

    go.drugbank.com/drugs/DB09280
    ApprovedInvestigational

    Consequently, lumacaftor increases successful production of CFTR ion channels and the total number of receptors available for use at the cell membrane for fluid and ion transport. … Approved for use by the Food and Drug Administration in July 2015 and by Health Canada in January 2016, Orkambi was the first combination product approved for the management of Cystic Fibrosis with delta-F508